Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Cardiac and Food Effect Study
NCT05478278Phase 1Completed
- Sponsor
- Usona Institute
- Start
- Jun 2022
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin in major depressive disorder (MDD), sponsored by Usona Institute. Started Jun 2022; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05478278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478278.